Organisation paid for research Program year 2025 Source: CMS Open Payments

Cares

Neither a doctor nor a teaching hospital

Research payments

$802,119

129 payments

Through program year 2025, Cares is reported as receiving $802,119 in research payments, across 129 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,050 1
2024 Research $26,972 6
2023 Research $2,000 1
2022 Research $196,046 21
2021 Research $96,473 16
2020 Research $96,546 14
2019 Research $383,031 70

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $511,982 93 payments
  2. AstraZeneca Pharmaceuticals LP $177,692 13 payments
  3. AbbVie, Inc. $72,922 12 payments
  4. Dompe Farmaceutici S.p.A. $24,022 5 payments
  5. Shire North American Group Inc $9,500 3 payments
  6. Allergan Inc. $3,000 1 payment
  7. Takeda Pharmaceuticals U.S.A., Inc. $3,000 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $511,982 93 payments
  2. An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) $126,612 6 payments
  3. A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men $48,413 8 payments
  4. Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) $24,022 5 payments
  5. Study of Durvalumab Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy $19,299 1 payment
  6. A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy ADRIATIC $16,581 4 payments
  7. A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE) $16,509 3 payments
  8. A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) $13,200 1 payment
  9. A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy $8,000 1 payment
  10. Study of the Effect of Shp647 As Maintenance Treatment in Participants With Moderate to Severe Ulcerative Colitis Who Achieved Clinical Response in Induction Studies $7,500 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record